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I: Introduction  
The 241st ENMC meeting took place in the Netherlands on the weekend of 15-17th February, 
2019, and was focused on Kennedy’s Disease (KD), also known as Spinal and Bulbar 
Muscular Atrophy (SBMA). The meeting involved twenty-four scientists working in academia, 
hospitals and industry from 8 different countries (Denmark, France, Germany, Israel, Italy, 
Spain, United Kingdom, USA) along with three patients’ representatives, including one who 
was also a representative of the USA patient group, The Kennedy’s Disease Association 
(KDA). The goal of this workshop was to bring together leading clinical and basic scientists 
working in the field of KD to discuss the current understanding of basic disease mechanisms 
and to share and update the most recent developments in clinical evaluation of patients, with 
the objective of increasing the prospects of developing and testing new  treatments that could 
effectively slow down disease progression in KD patients. The participants discussed recent 
developments in KD research and shared the most recent clinical observations. In this report, 
we summarize the presentations and discussions that took place during the workshop, which 
range from disease mechanisms, biomarker discovery, plans for an EU Registry for KD as 
well as an update on ongoing clinical trials. In addition, a dedicated session on the patient’s 
perspective was presented. 
Kenneth Fischbeck opened the meeting with an overview of the disease. Kennedy’s Disease 
(KD) also referred to as SBMA is a progressive X-linked neuromuscular disease characterized 
by bulbar and extremity muscle weakness, atrophy, and fasciculations. Affected males may 
show signs of androgen insensitivity, such as breast enlargement and reduced fertility. SBMA 
is caused by expansions of a CAG repeat in the androgen receptor (AR) gene. The disease 
typically presents in adult males with slowly progressive, relatively symmetrical, lower motor 
neuron weakness, perioral fasciculations, elevated creatine kinase, and decreased sensory 
potential amplitudes [1]. Common, but not invariable, manifestations are gynecomastia and a 
family history consistent with X-linked inheritance. Other non-neuromuscular features include 
Brugada syndrome [2], urinary retention [3], non-alcoholic fatty liver [4], and fatigue. Primary 
degeneration of both motor neurons and muscle occurs in SBMA; there are clinical features 
of denervation and loss of motor neurons in the spinal cord and brainstem, and also increased 
creatine kinase and histological evidence of muscle fiber degeneration. The disease 
phenotype can be partially rescued in mouse models with molecular correction in either 
muscle or the central nervous system [5-7]. 
The expanded CAG repeat in the AR gene encodes a polyglutamine tract in the transactivation 
domain of the AR protein (polyQ-AR), a part of the protein that is separate from the DNA- and 
hormone binding-domains [8]. The polyglutamine expansion is known to cause a loss of 
normal AR function and also a gain of function that is toxic to motor neurons and muscle. The 
mutant proteins have been shown to be toxic in cell culture and animal models, where they 
form neuronal inclusions and have a tendency to aggregate with increasing repeat length. The 
toxicity is greater with localization to the nucleus, where the mutant protein has aberrant 
interactions with other nuclear factors, leading to altered histone acetylation and 
transcriptional dysregulation, with adverse effects on axonal transport, signal transduction, 
and mitochondrial function, resulting in neuronal dysfunction and death [9, 10]. There is 
evidence for many paths to toxicity in animal models, and the challenge is to discern which 
paths are most important to the disease mechanism in patients. 
 
II: Disease Mechanisms: From AR structure to function in SBMA. 
Xavier Salvatella described the structural properties of the polyQ-AR associated with SBMA. 
Contrary to expectations the tract is not disordered but instead forms quite stable helices 
stabilized by an unusual type of hydrogen bond involving the glutamine side chain [11]. The 
size and the stability of these helices directly correlates with tract length, suggesting that 
changes in secondary structure upon polyQ tract elongation may contribute to onset of SBMA, 
possibly by altering that affinity that AR has for its binding partners [12]. Xavier Salvatella also 
showed how the molecular chaperones Hsp40 and Hsp70 interact with a specific motif in the 
activation domain of the AR and that this interaction contributes, on the one hand, to the 
efficient turnover of the inactive receptor and, on the other hand, to keeping the receptor 
soluble in the cytoplasm. Finally, he showed how it is possible to decrease the amount of 
monomeric and aggregated AR in a mouse model of SBMA by treating the mice with a small 
molecule that binds to Hsp70 and increases its affinity for intrinsically disordered substrates 
(unpublished data).  
 
Angelo Poletti described how the testosterone-induced misfolded species of the polyQ-AR 
impacts on degradative systems. Normally, polyQ-AR is processed by the proteasome, but 
after binding to testosterone polyQ-AR tends to aggregate and by losing its monomeric 
structure it cannot be recognized for proteasomal degradation. However, aggregates 
sequester potentially neurotoxic misfolded polyQ-AR species into a specific subcellular 
compartment, thus making polyQ-AR less harmful to cells. Aggregates could be removed by 
autophagy, but polyQ-AR blocks the autophagic flux limiting its own clearance. To enhance 
polyQ-AR degradation Poletti’s group has examined the possibility of modulating its routing to 
the two degradative systems, taking advantage of chaperones and co-chaperones function. 
They found that polyQ-AR can be efficiently removed from neuronal and muscle cells if the 
activity of a peculiar form of autophagy is enhanced. Overexpression of a small heat shock 
protein B8 (HSPB8) when proteasome activity is impaired, greatly reduces testosterone-
induced aggregation of polyQ-AR and facilitates its autophagic clearance. HSPB8 acts in 
conjunction with BAG3/HSPA8 and in association with the E3-ubiquitin ligase CHIP, 
generating a complex responsible for Chaperone-Assisted selective autophagy (CASA). The 
CASA complex recognizes misfolded proteins, which are then ubiquitinated by CHIP for 
SQSTM1/p62 recognition and dynein-mediated transport to microtubule organization center 
(MTOC) where autophagosomes are generated and lysosomes collected in normal neurons. 
Notably blockage of dynein transport does not result in polyQ-AR accumulation, as expected, 
but rather in an increased degradation via the proteasome prior to its aggregation. We found 
that this alternative degradation is facilitated by the presence of another HSPA8 co-chaperone, 
BAG1, which is induced when retrograde transport is blocked, and associates with 
HSPA8/CHIP in an opposite way to HSPB8/BAG3, leading to misfolded protein degradation 
via the proteasome. Thus, polyQ-AR degradation can be differentially obtained via 
proteasome and autophagy and this fine equilibrium is finely tuned by the relative expression 
of the HSPA8/CHIP1 partners: i) HSPB8/BAG3 to mediate polyQ-AR autophagic clearance, 
and ii) BAG1 to direct polyQ-AR proteasomal clearance. Based on these findings, Poletti 
proposed that factors capable of maintaining the correct ratio of autophagic and proteasome-
mediated degradation of polyQ-AR may prevent its accumulation and its consequent 
deleterious effects in SBMA. 
 
Maria Polanco described how the neurotoxicity of polyQ-AR can be modified by 
phosphorylation at specific sites, thus providing the rationale for the development of specific 
treatments for SBMA. Cyclin-2-dependent kinase (CDK2) phosphorylates polyQ-AR 
specifically at serine 96, increasing the stability and toxicity of polyQ-AR; and this 
phosphorylation is negatively regulated by the adenylate cyclase (AC) / protein kinase A (PKA) 
pathway [70]. Illana Gozes described various pituitary adenylyl cyclase activating polypeptide 
(PACAP) derivatives developed as activators of the AC/PKA pathway, and discussed how the 
native PACAP is involved in stress responses and regulates activity-dependent 
neuroprotective protein (ADNP). In order to develop a potential therapy, Illana Gozes 
synthesized a chemical analogue of the activating polypeptide of pituitary AC (PACAP), a 
potent activator of the AC / PKA pathway. Maria Polanco tested these analogs in a mouse 
model of SBMA. Chronic intranasal administration of this analog to SBMA mice reduced 
phosphorylation of polyQ-AR at serine 96, promoted its degradation and improved the SBMA 
outcome. These results show that non-invasive strategies based on the use of PACAP 
analogues may be a therapeutic option in SBMA. 
 
III. Disease Mechanisms: Peripheral polyQ-expanded AR mechanisms of mutant AR 
toxicity  
Although traditionally considered to be a motor neuron disease, recent findings strongly 
suggest that in addition to motor neurons, other tissues are also affected in SBMA. Indeed, 
SBMA is now considered a neuromuscular disorder rather than a pure motor neuron disease, 
since skeletal muscle may be a primary and early site of pathology. In this session, scientists 
presented findings that indicate that skeletal muscle represents a good target for therapeutic 
intervention as not only is it affected very early in the disease, as it may be more accessible 
to treatment than motor neurons which reside within the central nervous system.  
 
Carlo Rinaldi opened this session and began by describing how in SBMA and indeed all 
genetic conditions caused by mutations in ubiquitously expressed genes, the clinical picture 
is the result of a complex interplay between differentially affected tissues, which struggle to 
cooperate to maintain homeostasis. Carlo Rinaldi discussed the current understanding of the 
extra motor-neuron involvement in SBMA, with a particular focus on the primary muscle 
involvement, sensory neuropathy, and autonomic dysfunction, which are emerging as 
clinically highly impactful in patients’ quality of life and disease progression. Their thorough 
investigations are proving critical not only because they might provide important insights into 
common mechanisms of pathogenesis, but also because they may offer opportunities for 
single or combinatorial treatment strategies in the near future. In particular, he discussed 
ongoing research in his lab to disentangle the molecular mechanisms of muscle atrophy in 
SBMA and the effects of muscle-specific therapeutic targeting on motor neuron homeostasis. 
Additionally, studying the peripheral abnormalities in SBMA may offer the opportunity for direct 
functional assessments and repetitive samplings, therefore representing potentially 
exploitable biomarkers to track disease progression and/ or response to therapy, a critical 
need now that therapeutic opportunities are starting to reach the clinical trial phase. The 
second part of the talk was to introduce a new study aimed at identifying blood-based 
epigenetic biomarker to monitor the progression of muscle atrophy in SBMA.  Epigenetic 
biomarkers are one of the latest and most promising development in the field of biomarkers 
today and present highly attractive opportunities for clinical use. Moreover, epigenetic 
biomarker development involves the generation of omics data, which can be mined and 
analysed to objectively investigate the underlying pathways relevant for disease pathogenesis. 
By employing the state-of-the-art of epigenetic biomarker discovery in collaboration with a 
highly successful commercial partner, in the outstanding setting of the recently established 
Oxford Neuromuscular Translational Research Centre and in synergy with the largest 
dedicated SBMA clinic in UK, it is expected that this project will have a major impact on SBMA 
and other neuromuscular diseases. Lastly, this work will establish a framework of biomarker 
generation that could be useful for other human conditions. 
 
In their presentations, Maria Pennuto and Linda Greensmith presented compelling and 
complementary evidence to show that motor neuron dysfunction and loss in KD is associated 
with deficits and degeneration of skeletal muscle. Dr Pennuto showed genetic and 
pharmacological evidence that supports the concept that muscle atrophy is not only secondary 
to motor neuron degeneration. Rather, polyQ-AR has been shown to cause primary toxicity in 
muscle that in turn leads to motor neuron loss [13]. However, the mechanism through which 
polyQ-AR causes muscle atrophy remains to be elucidated. Maria Pennuto and Linda 
Greensmith reported evidence obtained in two different animal models of disease and in 
patient-derived muscle biopsies. Signs of neurogenic and myopathic atrophy can be detected 
in the skeletal muscle of transgenic mice overexpressing polyglutamine-expanded AR and 
knock-in SBMA mice [14, 15]. Myopathic processes and muscle atrophy precede spinal cord 
pathology in knock-in mice [15]. Muscles in transgenic and knock-in mice are intrinsically weak 
[16]. Fast-twitch muscles are mainly affected and display a glycolytic-to-oxidative fiber-type 
switching regardless of denervation with alteration in lipid homeostasis [17]. Early muscle 
pathology is present also in patients. Elevated levels of serum creatine kinase, myofiber 
degeneration and structures similar to central cores occur, even before clinical symptoms 
[18,19]. Glycolytic-to-oxidative myofiber-type switch, myofiber atrophy, and primary myogenic 
defects, such as necrotic myofiber and centrally located nuclei, are hallmarks of the disease 
as well [20, 21, 22, 23]. Importantly, genetic and pharmacologic silencing of polyQ-expanded 
AR expression in skeletal muscle prevented disease manifestations in mouse [5, 6]. Moreover, 
genetic and pharmacologic approaches to stimulate muscle anabolic pathways and inhibit 
catabolic pathways, and at the same time reduce polyQ-expanded AR toxicity ameliorated 
disease manifestations in mouse [6,14, 24]. 
 
Bilal Malik presented results from his study that aims to establish the genes and pathways that 
may be altered and may underlie motor neuron dysfunction in SBMA. Transcriptomic profiling 
of cultured primary embryonic motor neurons from SBMA mice showed that transcriptional 
dysregulation occurs early in development in SBMA motor neurons. Chmp7 was found to be 
downregulated in SBMA motor neurons, and was also altered in vivo in spinal cord of SBMA 
mice before symptom onset, and crucially it was upregulated in motor neurons derived from 
SBMA patient stem cells (iPSC-MNs). Furthermore, genes were enriched in SBMA motor 
neurons in several important pathways including p53, DNA repair, WNT and mitochondrial 
function. Functional analysis of SBMA embryonic motor neurons revealed dysfunctional 
mitochondria along with DNA damage, which may result from mitochondrial dysfunction and/or 
DNA repair gene dysregulation. These results highlight the interplay of multiple pathways in 
SBMA and suggest that this early coordinated dysregulation, especially Chmp7 dysfunction, 
may play a critical role in the development of disease. Bilal Malik is currently extending these 
findings and is undertaking a transcriptomic analysis of hindlimb muscle from SBMA mice as 
well as from muscle biopsies of SBMA patients. By analysing gene expression in muscle of 
two different models of SBMA (human and rodent), this team hopes to gain a better 
understanding of the mechanisms of muscle dysfunction, as well as provide targets for 
therapeutic intervention. 
 
The results presented in this session clearly confirm that SBMA should now be considered as 
a multisystem disorder and a greater understanding of the non-neuronal tissues affected in 
SBMA is a priority area for research. Future studies will therefore focus on unravelling the 
mechanisms of mutant AR toxicity in peripheral tissues to increase our understanding of 
tissue-specific functions of the AR.  
 
IV: Preclinical approaches to reduce polyQ-expanded AR toxicity.  
The discussion on potential novel preclinical approaches for SBMA focused on three main 
strategies to modulate AR activity by i) employing AR pharmacological antagonists; ii) 
silencing AR coactivators; and iii) enhancing AR degradation via induction of lysophagy, a 
lysosome specific form of autophagy.  
 
The first strategy was presented by Aria Baniahmad, who showed that new AR antagonists 
based on single benzene rings reduce polyglutamine-expanded AR aggregation. These novel 
AR antagonists target specifically the AR and the polyglutamine-expanded AR but act in a 
distinct manner, not yet uncovered, to inhibit AR activity compared to the therapeutically used 
antiandrogens (unpublished data; [25]). Manuela Basso illustrated the possibility to modulate 
the aberrant AR transcriptional activity in SBMA by decreasing the expression level of AR co-
activators. She showed preliminary evidence that silencing protein arginine methyl transferase 
6 (PRMT6) in vivo is beneficial in a transgenic mouse model of SBMA. PRMT6 is a co-activator 
of AR that potentiates the transcriptional activity of polyQ expanded AR by methylation of 
arginines present at the Akt-consensus site (RXRXXS) [26]. Of note, arginine methylation 
correlates with increased cellular toxicity while serine phosphorylation confers protection, 
highlighting the importance of modulating AR post-translational modifications (PTMs) in 
therapy. Along the same lines, Andrea Caricasole presented the pipeline of investigation of 
PTMs in huntingtin, another protein with polyQ expansion that leads to Huntington’s disease 
(HD). The talk highlighted the need to develop robust tools (reference proteins, antibodies) 
and assays (immunoassays and MS approaches) to detect and quantify PTMs in polyQ 
proteins and the challenges related to this approach. The inhibition of key factors contributing 
to cell toxicity can be achieved with different strategies, among which the use of adeno-
associated viruses. Giuseppe Ronzitti presented the development of a liver-based gene 
therapy approach for Pompe disease. The conclusions of this study indicate the safety and 
the efficacy of the treatment [27] and support the clinical translation of this approach. AR 
aggregates are present in muscle and motor neurons of SBMA patients. Paola Rusmini 
presented her recent work [28] in which she showed that trehalose, a disaccharide present in 
plants, fungi and some bacteria, activates lysophagy and enhances the clearance of 
aggregated AR. 
 
V: Towards a European registry for SBMA.  
The next presentation and discussion centered around the necessity to put in place an EU 
registry of SBMA patients, similar to that which has been implemented in the US for SBMA or 
for other rare diseases such as Huntington’s Disease in Europe.  
Davide Pareyson reported the experience of the Italian SBMA Registry, which has been 
developed to i) collect data useful for epidemiological and natural history studies, ii) test 
outcome measures, iii) facilitate recruitment in clinical trials, iv) develop biomarkers, and v) 
build a biorepository. Davide Pareyson presented the format of the Registry which is active at 
the https//:www.registronmd.it website [29] The minimal dataset to be collected has been 
agreed during a previous ENMC workshop [30]. The Registry is already predisposed to 
become an international registry as all items are in English [31]; only the section filled by the 
patients requires translation. It is a dual registry where the patient registers herself/himself, 
chooses a reference centre among three in Italy (Milan, Padua, Rome, with 22 other 
supporting centres), where the attending clinician collects the information and administers the 
clinical measures including the SBMA-FRS (SBMA-Functional Rating Scale) [32]; AMAT 
(Adult Myopathy Assessment Tool) [33]; 6MWT (6-minute walking test); self-administered 
questionnaires comprise the IIEF (International Index of Erectile Function) and the IPSS 
(International Prostatic Symptoms Score). Visits are repeated every year. All data are 
encrypted. Quantitative lower limb muscle MRI (qMRI) employing 3-point Dixon sequences 
[34] is performed in a subset of patients. Biological samples (serum, plasma, lymphocytes for 
immortalization, and in selected cases fibroblasts and myoblasts) are collected from 
consenting patients.  
Davide Pareyson next presented the data thus far collected on the 143 patients who registered 
and the 112 for whom the data were entered. Nineteen patients have performed the first follow 
up visit. The workshop discussed the importance of developing an international Registry 
starting from the Italian one (funded by Telethon Foundation-Italy). The possibility of joining 
directly the IT platform in Italy or to developed parallel interacting and interoperable Registries 
was discussed. Workshop participants considered and debated issues related to different 
national regulations, ethical requirements, compliance with the novel GDPR, and 
sustainability. Such points have been considered when developing the Italian Registry which 
is compliant with all requirements and can be an example to follow. All participants (including 
patients’ representatives) agreed on the importance of developing an International Registry in 
a joint common effort.  
 
The clinicians also agreed on the need for sharing data, particularly regarding outcome 
measures. Knowledge of the responsiveness of the different outcome measures is 
fundamental in the planning of clinical trial power and number of patients to be recruited. They 
agreed to build a clinical team coordinated by Davide Pareyson to share and pool the data on 
the outcome measures (AMAT, SBMA-FRS, 6MWT). They also agreed that it would be 
important to pool data on the qMRI. 
 
The Workshop participants also proposed that a European Biobank of tissues from animal 
models, as well as a SBMA Patient biobank would be extremely valuable resources for the 
SBMA research and clinical communities.  Moreover, resources generated within individual 
laboratories investigating SBMA and which form part of this KD Consortium (e.g. plasmids, 
cell lines) should be made available to the research centres that form part of the SBMA 
network. The scientists believe that making resources promptly accessible to this group could 
guarantee a more rapid and efficient progress of research on SBMA. However, to establish 
the animal and patient tissue biobanks it is clear that appropriate funding will need to be sought 
from European funding agencies. 
 
Section VI. Biomarkers and outcome measures for SBMA 
Apart from functional measures of disease status (e.g. walking distance, swallowing, grip 
strength), there are currently no reliable biomarkers for SBMA.  The Workshop participants 
recognized the urgent need for more accurate, reproducible biomarkers of disease 
progression in order to enable patient stratification and for the evaluation of disease 
progression, both of which are essential for effective clinical trials.  
 
Pierre-Francois Pradat presented results of neuroimaging studies which confirmed the 
multisystem nature of SBMA-associated pathology, and demonstrated that neurodegeneration 
is not limited to lower motor neurons but also involves the corticospinal tracts (CST) and 
widespread cerebral regions. Quantitative brain imaging studies revealed white matter 
alterations in the corticospinal tracts (CST), limbic system [35, 36], brainstem and cerebellum 
[38]. Voxel-based morphometry (VBM) of SBMA cohorts revealed gray matter atrophy in the 
frontal lobes and in the brainstem [35-38]. Frontal hypometabolism has been detected by 
positron-emission-tomography (PET) [38]. Neuropsychological studies have detected subtle 
frontal dysfunction in small study populations [40, 41], which were not confirmed in larger 
cohorts [42, 43]. With recent technological advances, spinal imaging now offers unique 
opportunities to appraise lower motor neuron degeneration. It has been applied successfully 
to other motor neuron diseases such as ALS [44-46], and SMA [47, 48], to characterize gray 
and white matter pathology. There is an ongoing monocentric longitudinal study to evaluate 
spinal cord imaging in SBMA patients and test whether it is a promising candidate biomarker 
(NCT02885870).   
 
John Vissing next presented data on the disease phenotype in a cohort of 40 patients affected 
by SBMA and natural history data on 29 SBMA patients followed for 1 year. Phenotypic data 
were based on muscle MRI, functional tests and questionnaires. Muscle MRI showed that fat 
replacement of muscle was most pronounced in posterior muscle groups of thigh and calves 
and in the tongue [49]. This pattern together with relatively preserved sartorius, gracilis and 
tibialis anterior muscles suggest a diagnosis of SBMA. Muscle fat content correlated with 
muscle strength, SBMA functional rating scale score, and 6-minute walk test distance. It was 
also shown that muscle contractility is impaired in SBMA patients vs healthy subjects, even 
when correcting for fat content, and fat seemed to have an adverse effect on contractility more 
than could be explained by the replacement of muscle alone [50].  
 
One-year follow-up showed a significant increase in muscle fat by on average 2 % in all studied 
muscle groups [51]. Only a few strength measures (knee extension and handgrip) decreased 
and functional rating scores did not change, while the 6MWT dropped significantly from 362 
to 336m. The findings suggest that Dixon MRI of muscle is a suitable candidate as an outcome 
measure for natural history or treatment studies in SBMA, along with the 6-minute walk test 
and handgrip strength [52]. 
 
Pietro Fratta presented an update from the UK National Kennedy’s Disease Clinic, focussing 
on disease biomarkers. Since the first KD ENMC Meeting in 2015, a dedicated clinic was 
started in London and now more than 60 KD patients are seen and followed up yearly. There 
has been focus on developing biomarkers for disease progression, as these are essential for 
effective clinical trials. Through the collection of plasma and serum at each visit, the UK group 
was able to measure molecules that indicate the damage occurring in the muscles and 
neurons of patients. Results highlighted how neuronal damage appears to be occurring at very 
low levels, whilst there is prominent active muscle damage, and markers such as creatinine 
show promise for use in clinical trials [53-55]. Further work analysing miRNAs in blood also 
confirmed a high degree of myopathic alterations. In parallel to blood analysis, the UK group 
also investigated muscle MRI as a tool to assess disease, and, when comparing KD patients 
with ALS patients and controls, they identified very specific patterns of muscle involvements 
that correlate with disease severity [56]. Overall, they suggest that a combined use of blood 
molecules and imaging studies, along with refined functional rating scales (discussed by Luca 
Zampedri) should be used in clinical trials. 
 
Luca Zampedri, a specialist research nurse from UCL in London, next described the functional 
assessments the UCL team is employing in the dedicated National KD Clinic at Queen Square.  
People with SBMA attending the clinic undergo a battery of tests consisting of functional rating 
scales, 6MWT, AMAT, as well as myometries. Functional assessments collected from 128 
people in three European services are currently being reviewed with Rash Analysis, by 
comparing each measures difficulty with the cohort’s ability to fulfil the required tasks. 
Preliminary data have shown the need to re-score some measures as to better capture the 
high functional variability found amongst KD sufferers. 
 
In addition to participating in research, the majority of patients find it useful to obtain tangible 
measurements of their physical fitness. However, some participants have reported feeling 
extremely fatigued for days following testing, a factor not necessarily dependent on disease 
progression. Moreover, the potential negative psychological impact of functional assessments 
in a condition should not be overlooked, and motivation remains important in the patients’ 
willingness and ability to engage with testing. Certain tests such as AMAT and 6MWT, which 
are designed to capture both muscular strength and endurance, can be particularly 
demanding. It has been suggested that the 2 minutes walking test (2MWT) might be a valid 
alternative to the 6MWT in a variety of neuromuscular conditions including SBMA [52]. A 
shorter, less demanding assessment might be completed by those experiencing advanced 
lower limb impairment and at the same time reduce post-testing fatigability. Systematic 
recording of intermediate times is required to evaluate the validity of the 2MWT in our cohorts.  
 
Beyond the use of bulbar scales there exist few minimally invasive methods to capture bulbar 
function. Tongue pressure measurements have been suggested to be a reliable biomarker in 
SBMA [57, 58]. In the UK cohort, tongue pressure measurements have been shown to be 
lower in people with SBMA with normal bulbar functional score when compared to healthy 
controls. However, tongue pressure did not capture disease progression, at least over 12 and 
24 months. 
 
As part of the process of revising the assessments used in SBMA, the possibility of merging 
the existing scales into one has been suggested in order to eliminate repeated measurements. 
However, whilst accounting for both ceiling and floor effects and for participants’ tolerability, 
an important objective should be the preservation of historical data for comparison.   
 
Section VII. Clinical Trials for SBMA  
Kenneth Fischbeck next presented an overview of recent clinical trials in SBMA. Over the past 
16 years a number of treatments have been found to be effective in mouse models of SBMA; 
the challenge has been to convert these findings into effective treatment in patients. Most 
promising in this regard are interventions close to the mutant AR protein, including androgen 
reduction, selective AR modulation, altering AR PTMs, and decreasing AR expression. The 
toxicity of the mutant AR has been shown to be dependent on androgens in transgenic flies 
and mice, and anti-androgen treatment (leuprorelin) blocks the disease onset and prevents 
the motor deficit in mice [59]. Three randomized, placebo-controlled trials have addressed 
whether such treatment works in patients, and none showed significant effects on the primary 
outcome measures of swallowing and muscle strength and function, although each had 
indications of secondary benefit [60-62]. A 7-year open-label follow-up study showed that 
patients did better with the androgen-reducing agent leuprorelin, and this drug has now been 
approved for SBMA treatment in Japan [63]. 
 
Other therapeutic targets close to the genetic defect include selective AR modulation 
(SARMs), PTM of the disease gene product, and disease gene expression. ASC-JM17 is an 
AR modulator that accelerates the mutant protein degradation, activates cellular protective 
responses through Nrf1/Nrf2, and rescues the phenotype in transgenic flies and mice [64]. 
Overexpression of insulin-like growth factor 1 (IGF-1) blocks AR toxicity through 
phosphorylation by Akt, and IGF-1 treatment improves muscle pathology and behavior in 
SBMA mice [65]. SBMA patients have low serum IGF-1, allowing room for therapeutic benefit. 
A recent placebo-controlled clinical trial of an IGF-1 mimetic showed a significant positive 
effect on the primary outcome measure (change in thigh muscle volume) [66]. The drug was 
well tolerated, but induced antibodies against endogenous IGF-1, which precluded further 
development. AAV-mediated intravenous delivery of a microRNA targeting the 3’UTR of the 
AR mRNA resulted in reduction in mutant AR protein levels and mitigation of disease 
manifestations in SBMA mice [67]. Finally, an antisense oligonucleotide targeting AR reduces 
mutant mRNA and protein levels and mitigates disease manifestations with peripheral or 
central administration in mice [6, 7]; this too may be worth pursuing as a candidate therapeutic 
for SBMA. 
 
Gianni Soraru’ discussed findings which suggest that beta2-agonist stimulation of muscle may 
represent a therapeutic avenue for SBMA and describe plans to undertake a clinical trial of 
clenbuterol in SBMA patients. Treatment of SBMA knock-in mice with clenbuterol started at 
disease onset ameliorated motor function and extended survival [68]. Moreover, beta2-
agonists have been found to be effective in improving motor function without relevant adverse 
events in a small cohort of SBMA patients [69]. To establish safety and efficacy of clenbuterol 
as a cure for SBMA, Gianni Soraru’s team are conducting a multicenter, phase II, randomized, 
double-blind, parallel-group, single dose, placebo-controlled trial. The effectiveness of 
clenbuterol will be assessed with a number of outcome measures, including measures of the 
motor function, such as the 6MWT and the AMAT [33]; established rating scale such as the 
SBMA-FRS [32]; the forced vital capacity, a measure of respiratory muscle function; and 
quality of life by the ALSAQ–40 Questionnaire.  
 
The tolerability of clenbuterol will be assessed by listing and counting all adverse events 
occurring during the trial. Ninety eligible subjects will be randomized to receive either 
clenbuterol or placebo tablets for 12 months. Adverse events, serious adverse events, 
suspected/unexpected adverse events, drug-related events will be recorded, along with 
duration, attribution to treatment, outcome and actions.  To monitor potential side effects on 
cardiovascular system, a full cardiac protocol will be employed including echocardiogram, 
standard and 24 hours Holter EKG. Given the concern about a potential muscle damage 
raised by finding increased CK levels in SBMA patients treated with clenbuterol [69], the trial 
will also evaluate any muscle involvement by the means of the muscle MRI findings of thighs 
(i.e. presence of edema, degree of atrophy and/or fat substitution).  
 
 
VIII. Patients perspective. 
The patient representatives, Marco Bertolotti and Gianni Fabris discussed the importance of 
collaboration between patient associations, clinicians and basic scientists for the 
advancement of SBMA. The role of patient associations in the dissemination of information 
was highlighted, for example about the importance and need for national registries as a means 
to update the SBMA patient community in international scientific efforts in SBMA research. 
Edward Meyertholen from the USA was present during the Workshop as a representative of 
the patients’ association – The Kennedy’s Disease Association (KDA), supporting 
relationships and exchanges between patients and researchers from all over the world. 
Edward Meyertholen gave a brief outline of the KDA, which was founded in 2000 by Terry and 
Susanne Waite.  The KDA is a patient-centric organization developed to meet the needs of 
those with KD, which has concentrated its efforts on education and research; it has been very 
successful to achieving these ends. 
With regard to education, the KDA maintains a website with information about KD, and it is 
one of the best sites for newly diagnosed patients to get information regarding the signs and 
symptoms of KD.  In addition to its website, the KDA sends out a monthly newsletter and it 
sponsors an annual conference that brings together researchers with patients, carriers and 
their families.  During the Annual Conference information is presented that offers advice to  
KD patients and their families on how to live with KD.  In addition, the KDA Conference has 
leading researchers present their recent scientific and clinical findings.  Feedback from people 
attending KDA conferences consistently rates interaction with the researchers as one of the 
highlights of the conference. Nonetheless, there remains a wide gap between the researchers 
and patients not only in scientific knowledge but also in expectations.  Researchers should be 
cognizant of these gaps when their research is publicized.   
 
With regard to research, the KDA has develop a strong and growing grant program.  The KDA 
awarded its first grant in 2003 and since then, has given almost 1 million dollars in funding.  
While a small group, the KDA has been successful at fundraising to support this program and 
more than 80% of its budget goes to funding grants.   This program has grown from awarding 
a single grant of $20,000 in 2003 to having funded four grants at $50,000 each in 2018.  It is 
expected that the funding levels will increase again in 2019.  Generally, the program has been 
directed toward supporting young researchers (post docs, assistant professors).  Grants have 
been awarded to over 20 researchers across the world.  Feedback from the grantees has 
indicated that these grants have been instrumental in helping them advance their careers as 
well as maintaining their interest in researching KD. 
 
IX: Next Steps 
In order to increase scientific and clinical collaborations among groups working in different 
countries, it was agreed that an International Conference on SBMA should be organized. The 
Workshop participants highlighted the importance of researchers collaborating with patients’ 
associations in the organization of the meeting, in order to reinforce the communication of 
scientific and clinical progress to SBMA patients and families, and to providing the community 
with the possibility of directly collaborating in the research process. 
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